Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis

Author(s): Tetsumei Urano*, Yuko Suzuki, Takayuki Iwaki, Hideto Sano, Naoki Honkura, Francis J. Castellino.

Journal Name: Current Drug Targets

Volume 20 , Issue 16 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The fibrinolytic system consists of a balance between rates of plasminogen activation and fibrin degradation, both of which are finely regulated by spatio-temporal mechanisms. Three distinct inhibitors of the fibrinolytic system that differently regulate these two steps are plasminogen activator inhibitor type-1 (PAI-1), α2-antiplasmin, and thrombin activatable fibrinolysis inhibitor (TAFI). In this review, we focus on the mechanisms by which PAI-1 governs total fibrinolytic activity to provide its essential role in many hemostatic disorders, including fibrinolytic shutdown after trauma. PAI-1 is a member of the serine protease inhibitor (SERPIN) superfamily and inhibits the protease activities of plasminogen activators (PAs) by forming complexes with PAs, thereby regulating fibrinolysis. The major PA in the vasculature is tissue-type PA (tPA) which is secreted from vascular endothelial cells (VECs) as an active enzyme and is retained on the surface of VECs. PAI-1, existing in molar excess to tPA in plasma, regulates the amount of free active tPA in plasma and on the surface of VECs by forming a tPA-PAI-1 complex. Thus, high plasma levels of PAI-1 are directly related to attenuated fibrinolysis and increased risk for thrombosis. Since plasma PAI-1 levels are highly elevated under a variety of pathological conditions, including infection and inflammation, the fibrinolytic potential in plasma and on VECs is readily suppressed to induce fibrinolytic shutdown. A congenital deficiency of PAI-1 in humans, in turn, leads to life-threatening bleeding. These considerations support the contention that PAI-1 is the primary regulator of the initial step of fibrinolysis and governs total fibrinolytic activity.

Keywords: Plasminogen activator inhibitor type 1 (PAI-1), tissue-type plasminogen activator (tPA), fibrinolysis, fibrinolytic potential, trauma, fibrinolysis shutdown.

[1]
Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82(2): 259-70.
[PMID: 10605712]
[2]
Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93(4): 647-54.
[http://dx.doi.org/10.1160/TH04-12-0842] [PMID: 15841308]
[3]
Urano T, Castellino FJ, Suzuki Y. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost 2018.
[http://dx.doi.org/10.1111/jth.14157] [PMID: 29779246]
[4]
Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157(3): 291-8.
[http://dx.doi.org/10.1111/j.1365-2141.2012.09074.x] [PMID: 22360729]
[5]
Rijken DC, Uitte de Willige S. Inhibition of Fibrinolysis by Coagulation Factor XIII. BioMed Res Int 2017.20171209676
[http://dx.doi.org/10.1155/2017/1209676] [PMID: 28761875]
[6]
Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: At the nexus of fibrinolysis and inflammation. Thromb Res 2012; 129(3): 314-9.
[http://dx.doi.org/10.1016/j.thromres.2011.10.031] [PMID: 22113149]
[7]
Plug T, Meijers JC. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2016; 14(4): 633-44.
[http://dx.doi.org/10.1111/jth.13261] [PMID: 26786060]
[8]
Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010; 8(5): 868-76.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03787.x] [PMID: 20128866]
[9]
Law RH, Caradoc-Davies T, Cowieson N, et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012; 1(3): 185-90.
[http://dx.doi.org/10.1016/j.celrep.2012.02.012] [PMID: 22832192]
[10]
Castellino FJ. PlsminogenMolecular Basis on Thrombosis and Haemostasis. Marcel Dekker 1995; pp. 495-515.
[11]
Tomczyk M, Suzuki Y, Sano H, Brzoska T, Tanaka H, Urano T. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis. Thromb Res 2016; 143: 28-33.
[http://dx.doi.org/10.1016/j.thromres.2016.04.018] [PMID: 27179129]
[12]
Urano T, Nishikawa T, Nagai N, Takada Y, Takada A. Amounts of tPA and PAI-1 in the euglobulin fraction obtained at different pH: Their relation to the euglobulin clot lysis time. Thromb Res 1997; 88(1): 75-80.
[http://dx.doi.org/10.1016/S0049-3848(97)00193-X] [PMID: 9336876]
[13]
Urano T, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada A. Fluctuation of tPA and PAI-1 antigen levels in plasma: Difference of their fluctuation patterns between male and female. Thromb Res 1990; 60(2): 133-9.
[http://dx.doi.org/10.1016/0049-3848(90)90292-K] [PMID: 2126399]
[14]
Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63(1): 82-6.
[http://dx.doi.org/10.1055/s-0038-1645691] [PMID: 2111051]
[15]
Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66(4): 474-8.
[http://dx.doi.org/10.1055/s-0038-1646441] [PMID: 1796399]
[16]
Urano T, Suzuki Y, Arakida M, Kanamori M, Takada A. The expression of exercise-induced tPA activity in blood is regulated by the basal level of PAI-1. Thromb Haemost 2001; 85(4): 751-2.
[http://dx.doi.org/10.1055/s-0037-1615669] [PMID: 11341521]
[17]
Madison EL, Kobe A, Gething MJ, Sambrook JF, Goldsmith EJ. Converting tissue plasminogen activator to a zymogen: A regulatory triad of Asp-His-Ser. Science 1993; 262(5132): 419-21.
[http://dx.doi.org/10.1126/science.8211162] [PMID: 8211162]
[18]
Urano T, deSerrano VS, Urano S, Castellino FJ. Stimulation by fibrinogen of the amidolytic activity of single-chain tissue plasminogen activator. Arch Biochem Biophys 1989; 270(1): 356-62.
[http://dx.doi.org/10.1016/0003-9861(89)90038-6] [PMID: 2494944]
[19]
Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139(1): 245-56.
[http://dx.doi.org/10.1083/jcb.139.1.245] [PMID: 9314543]
[20]
Suzuki Y, Mogami H, Ihara H, Urano T. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 2009; 113(2): 470-8.
[http://dx.doi.org/10.1182/blood-2008-03-144279] [PMID: 18922856]
[21]
Suzuki Y, Yasui H, Brzoska T, Mogami H, Urano T. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood 2011; 118(11): 3182-5.
[http://dx.doi.org/10.1182/blood-2011-05-353912] [PMID: 21791417]
[22]
Suzuki Y, Sano H, Tomczyk M, Brzoska T, Urano T. Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio 2016; 6(5): 469-76.
[http://dx.doi.org/10.1002/2211-5463.12057] [PMID: 27419052]
[23]
Lamba D, Bauer M, Huber R, et al. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J Mol Biol 1996; 258(1): 117-35.
[http://dx.doi.org/10.1006/jmbi.1996.0238] [PMID: 8613982]
[24]
Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1(7): 1575-9.
[http://dx.doi.org/10.1046/j.1538-7836.2003.00279.x] [PMID: 12871293]
[25]
Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88(5 Pt 1): 2030-4.
[http://dx.doi.org/10.1161/01.CIR.88.5.2030] [PMID: 8222095]
[26]
Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332(10): 635-41.
[http://dx.doi.org/10.1056/NEJM199503093321003] [PMID: 7845427]
[27]
Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83(2): 351-6.
[PMID: 8286735]
[28]
Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104(13): 3943-8.
[http://dx.doi.org/10.1182/blood-2004-04-1439] [PMID: 15315974]
[29]
Stringer HAR, Vanswieten P, Heijnen HFG, Sixma JJ, Pannekoek H. On the function of pai-1 in platelet-rich thrombi produced in the chandler loop. Thromb Haemost 1993; 69(6): 582.
[30]
Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14(9): 1452-8.
[http://dx.doi.org/10.1161/01.ATV.14.9.1452] [PMID: 8068607]
[31]
Hosokawa K, Ohnishi-Wada T, Sameshima-Kaneko H, et al. Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model. Thromb Res 2016; 146: 69-75.
[http://dx.doi.org/10.1016/j.thromres.2016.09.002] [PMID: 27611498]
[32]
Urano T, Kojima Y, Takahashi M, et al. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Jpn J Physiol 1993; 43(2): 221-8.
[http://dx.doi.org/10.2170/jjphysiol.43.221] [PMID: 8355419]
[33]
Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: Results of an observational pilot study. Ann Intensive Care 2019; 9(1): 19.
[http://dx.doi.org/10.1186/s13613-019-0499-6] [PMID: 30701381]
[34]
Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: The past, present, and future. J Thromb Haemost 2019; 17(6): 852-62.
[http://dx.doi.org/10.1111/jth.14450] [PMID: 30985957]
[35]
collaborators C-, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 377(9771): 1096-10101 2011.
[36]
Yasui H, Donahue DL, Walsh M, Castellino FJ, Ploplis VA. Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury. Am J Physiol Lung Cell Mol Physiol 2016; 311(1): L74-86.
[http://dx.doi.org/10.1152/ajplung.00429.2015] [PMID: 27190065]
[37]
Castellino FJ, Liang Z, Davis PK, et al. Abnormal whole blood thrombi in humans with inherited platelet receptor defects. PLoS One 2012; 7(12)e52878
[http://dx.doi.org/10.1371/journal.pone.0052878] [PMID: 23300803]
[38]
Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2: 16037.
[http://dx.doi.org/10.1038/nrdp.2016.37] [PMID: 27250996]
[39]
Jeleńska MM. Coagulation parameters as predictors of DIC in patients with intact aortic aneurysm. Hamostaseologie 2004; 24(3): 162-6.
[http://dx.doi.org/10.1055/s-0037-1619626] [PMID: 15314700]
[40]
Madoiwa S, Someya T, Hironaka M, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res 2007; 119(2): 229-40.
[http://dx.doi.org/10.1016/j.thromres.2006.01.017] [PMID: 16524621]
[41]
Madoiwa S. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC. J Intensive Care 2015; 3: 8.
[http://dx.doi.org/10.1186/s40560-015-0075-6] [PMID: 27408725]
[42]
Moore HB, Moore EE, Huebner BR, et al. Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator. J Trauma Acute Care Surg 2017; 83(6): 1014-22.
[http://dx.doi.org/10.1097/TA.0000000000001718] [PMID: 29190254]
[43]
Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23(11): 1835-42.
[http://dx.doi.org/10.1097/00003246-199511000-00009] [PMID: 7587259]
[44]
Sentilhes L, Winer N, Azria E, et al. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med 2018; 379(8): 731-42.
[http://dx.doi.org/10.1056/NEJMoa1800942] [PMID: 30134136]
[45]
Meizoso JP, Dudaryk R, Mulder MB, et al. Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid. J Trauma Acute Care Surg 2018; 84(3): 426-32.
[http://dx.doi.org/10.1097/TA.0000000000001792] [PMID: 29298240]
[46]
Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327(24): 1729-33.
[http://dx.doi.org/10.1056/NEJM199212103272406] [PMID: 1435917]
[47]
Iwaki T, Nagahashi K, Takano K, et al. Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation. Thromb Haemost 2017; 117(5): 860-9.
[http://dx.doi.org/10.1160/TH16-07-0572] [PMID: 28229167]
[48]
Iwaki T, Tanaka A, Miyawaki Y, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 9(6): 1200-6.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04288.x] [PMID: 21486382]
[49]
Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: A clinical review. J Thromb Haemost 2018.
[http://dx.doi.org/10.1111/jth.14160] [PMID: 29847021]
[50]
Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3(1): 35-45.
[http://dx.doi.org/10.1111/j.1538-7836.2004.00827.x] [PMID: 15634264]
[51]
Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72(1): 1-22.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19970703)72:1<1: AID-IJC1>3.0.CO;2-Z] [PMID: 9212216]
[52]
Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010; 125(5): 377-81.
[http://dx.doi.org/10.1016/j.thromres.2009.11.034] [PMID: 20079523]
[53]
Khan SS, Shah SJ, Klyachko E, Baldridge AS, Eren M, Place AT, et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci Adv 3(11) 2017
[http://dx.doi.org/10.1126/sciadv.aao1617]
[54]
Eren M, Boe AE, Murphy SB, et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci USA 2014; 111(19): 7090-5.
[http://dx.doi.org/10.1073/pnas.1321942111] [PMID: 24778222]
[55]
Wyseure T, Declerck PJ. Novel or expanding current targets in fibrinolysis. Drug Discov Today 2014; 19(9): 1476-82.
[http://dx.doi.org/10.1016/j.drudis.2014.05.025] [PMID: 24886765]
[56]
Simone TM, Higgins SP, Higgins CE, Lennartz MR, Higgins PJ. Chemical antagonists of plasminogen activator inhibitor-1: Mechanisms of action and therapeutic potential in vascular disease. J Mol Genet Med 2014; 8(3): 125.
[http://dx.doi.org/10.4172/1747-0862.1000125] [PMID: 26110015]
[57]
Ibrahim AA, Yahata T, Onizuka M, et al. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells 2014; 32(4): 946-58.
[http://dx.doi.org/10.1002/stem.1577] [PMID: 24155177]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 16
Year: 2019
Page: [1695 - 1701]
Pages: 7
DOI: 10.2174/1389450120666190715102510

Article Metrics

PDF: 42
HTML: 4
EPUB: 1

Special-new-year-discount